⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Protium Science and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Protium Science
↗Seongnam-si, South Korea
Protium Science is a specialized Contract Development and Analysis Organization (CDAO) based in South Korea. The company provides comprehensive Chemistry, Manufacturing, and Controls (CMC) services, including cell line development, process development, formulation, and quality analysis for biopharmaceutical companies ranging from early-stage startups to commercial manufacturing.
As a subsidiary of TiumBio, Protium Science acts as a strategic partner in the biopharmaceutical ecosystem, often collaborating with other firms to provide integrated CDMO services. They have expanded their service offerings to include Antibody-Drug Conjugate (ADC) development, peptide analysis, and support for biosimilar development, aiming to reduce development risks and accelerate time-to-market for their clients.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Ownership:subsidiary
Status:operating
FUNDING
Stage:Series A
Total Raised:$1.5M
PIPELINE
Stage:Discovery
Lead Drug Stage:N/A (Service Provider)
Modalities:Antibody-Drug Conjugate (ADC), Bispecific antibodies, Peptides, Biosimilars
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:TiumBio
Key Partnerships:TiumBio (Parent company), STgen Bio (CDMO collaboration), Patheon (Overseas CMO MOU), KyungDong Pharm (Biosimilar development), MUSTBIO (Bispecific antibody development), Reyon Pharmaceutical (CDMO cooperation), BXPLANT (Strategic partnership)
COMPETITION
Position:Niche Player
LEADERSHIP
Key Executives:
Ahn Yong-ho - CEO
Kim Hun-teak - CEO
LINKS
Website:protiumscience.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Protium Science. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.